Catalyst Database

10/9/24- Ph1 CTA cleared by Health Canada. 11/7/24- First subject dosed. 12/3/24- Prelim data from first 3 SAD cohorts. 1/16/25- Completed all 5 SAD cohorts & advanced to MAD cohorts with topline data in H1 2025. 3/14/25- Commences dosing in Ph1a/b.

12/2/24- First participants dosed with interim data in Q2 2025.

4/3/24- Initiated Ph2 trial with topline data in H1 2025.

GOBLET study. 11/9/23- SCCA cohort positive interim results. 2/14/24- Enrollment expansion of anal cancer cohort. 5/15/24- Preliminary collaboration w/ GCAR. 5/24/24- Abstract presentation at ASCO '24 on June 1st. 10/4/24 Updated efficacy data from cohort 4 in 2L /later anal cancer in H1 2025.

GlycoMimetics collaboration in US. 6/4/24 Present comprehensive results, meaningful mOS data. 1/3/24 Completes Enrollment in Phase 3 Bridging Study in China, topline data in H1 2025.

QUALITY study. 4/30/24- First patient enrolled. 8/8/24- Reached full enrollment. 1/27/25- Reported topline data, met primary endpoint. 2/6/25- Topline results of Ph2b extension study in Q2 2025. Move forward to request end of Phase 2 meeting with FDA.

Present data at ESMO IO '23 on 12/07/23. Phase 2 cohort of casdozokitug with toripalimab is ongoing. Combo data in H1 '25

COACH Trial: 9/3/24 Complete enrollment in Q3 '24. 11/14/24- Topline 26-wk data in Q2 '25

STAAR study. H1 '24 Complete patient dosing. 2/12/24 FDA advises a single study for BLA approval; EMA granted PRIME eligibility. 3/12/24- Deferred additional investment for Ph3 up until collab partnership is secured. 10/22/24 Alignment w/ FDA on Accelerated Approval Pathway; 52-week eGFR slope data by H1 '25 & BLA in H2 2025.

MAPLE-HCM trial (oHCM). Q3 '24- Enrollment completed in MAPLE-HCM trial comparing aficamten to metoprolol. Topline results in H1 2025.